推薦產品
等級
analytical standard
化驗
~95% (HPLC)
~95%
技術
HPLC: suitable
gas chromatography (GC): suitable
應用
food and beverages
格式
neat
儲存溫度
−20°C
SMILES 字串
CC(O)=O.CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c3c(C)cc4c(C(C)C)c(O)c(O)c(C=O)c4c3O
InChI
1S/C30H30O8.C2H4O2/c1-11(2)19-15-7-13(5)21(27(35)23(15)17(9-31)25(33)29(19)37)22-14(6)8-16-20(12(3)4)30(38)26(34)18(10-32)24(16)28(22)36;1-2(3)4/h7-12,33-38H,1-6H3;1H3,(H,3,4)
InChI 密鑰
NIOHNDKHQHVLKA-UHFFFAOYSA-N
應用
有关合适仪器技术的更多信息，请参考产品分析证书。如需进一步支持，请联系技术服务部门。
生化／生理作用
据报道可以抑制胃蛋白酶原向胃蛋白酶的自溶转化。
訊號詞
Warning
危險聲明
危險分類
Acute Tox. 4 Oral - Carc. 2
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
個人防護裝備
Eyeshields, Gloves, type P3 (EN 143) respirator cartridges
Christian Billard
Molecular cancer research : MCR, 10(6), 673-676 (2012-04-03)
Despite real advances made in chemoimmunotherapy, chronic lymphocytic leukemia (CLL) is still an incurable disease. New therapeutic strategies based on the restoration of the cell death program seemed relevant. Some members of the Bcl-2 family are critical players in the
Neal Ready et al.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 6(4), 781-785 (2011-02-04)
AT-101 is an inhibitor of Bcl-2 family proteins including Bcl-2, Bcl-xL, Mcl-1, and Bcl-w. In vivo and in vitro studies have exhibited broad activity of AT-101, including synergy with docetaxel in non-small cell lung cancer tumor models. We conducted a
Inhibition of pepsinogen activation by gossypol.
T D Tanksley et al.
The Journal of biological chemistry, 245(23), 6456-6461 (1970-12-10)
Studies on the nature of the inhibition by gossypol of the transformation of pepsinogen to pepsin.
R C Wong et al.
The Journal of biological chemistry, 247(5), 1625-1631 (1972-03-10)
Rebecca Suk Heist et al.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 5(10), 1637-1643 (2010-09-03)
AT-101 is an oral, pan Bcl-2 family protein inhibitor that has demonstrated activity in small cell lung cancer (SCLC) models. A phase I/II study was conducted combining AT-101 with topotecan in relapsed and refractory SCLC. An open-labeled multicenter phase I/II
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務